In the realm of colorectal cancer (CRC), the intricate interplay between the gut microbiota and the etiological dynamics of this disease has emerged as a focal point of investigation. The gut microbiota, comprising a diverse array of microorganisms inhabiting the gastrointestinal tract, profoundly influences local mucosal immunity, inflammation, and metabolic processes. Dysbiosis, characterized by aberrant microbial community structures, has been associated with heightened CRC risk, primarily through the promotion of chronic inflammation, alteration of microbial metabolites, and disruption of intestinal barrier integrity. Conversely, specific commensal bacteria have demonstrated protective effects against CRC initiation and progression, primarily by modulating immune responses, enhancing mucosal barrier function, and producing anti-tumorigenic metabolites. Promisingly, therapeutic interventions targeting gut microbiota, such as fecal microbiota transplantation and microbial-based therapeutics, hold potential for CRC prevention and treatment. However, achieving a comprehensive understanding of the complex interactions among host genetics, environmental factors, and the gut microbiota in CRC remains a critical research frontier. Advancements in high-throughput sequencing technologies, coupled with multi-omics approaches, are poised to unravel the nuanced mechanisms underlying gut microbiota-CRC interactions, ultimately paving the way for precision medicine strategies tailored to individual patients.
This Research Topic aims elucidate the pivotal role of gut microbiota in colorectal cancer (CRC), delving into its multifaceted implications for disease etiology, progression, and therapeutic interventions. By unraveling the intricate interplay between host-microbiota interactions and CRC pathogenesis, we seek to uncover novel biomarkers for risk assessment and prognosis, paving the way for precision medicine strategies. Additionally, our objective is to decipher the mechanistic underpinnings of dysbiosis-mediated carcinogenesis, informing the development of targeted microbiota-based therapeutics and dietary interventions. Ultimately, these endeavors aim to advance our understanding of CRC at the molecular level, fostering the translation of microbiome research into transformative clinical applications for improved patient outcomes.
We welcome submissions focused on, but not limited to, the following subtopics:
● Exploring the mechanisms underlying the involvement of gut microbiota in the occurrence, development, recurrence, metastasis, and treatment resistance of CRC.
● Unveiling the complex interplay between host-microbiota interactions and the pathogenesis of CRC, seeking novel biomarkers for risk assessment and prognosis.
● Clinical and basic research on the role of gut microbiota in early-onset CRC.
● Studying the co-cultivation of organoids and microbiota to elucidate mechanisms of colorectal development.
Keywords:
Gut microbiota, Colorectal cancer, Patient-derived organoids, Co-cultivation of organoids and microbiota, Early onset colorectal cancer
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
In the realm of colorectal cancer (CRC), the intricate interplay between the gut microbiota and the etiological dynamics of this disease has emerged as a focal point of investigation. The gut microbiota, comprising a diverse array of microorganisms inhabiting the gastrointestinal tract, profoundly influences local mucosal immunity, inflammation, and metabolic processes. Dysbiosis, characterized by aberrant microbial community structures, has been associated with heightened CRC risk, primarily through the promotion of chronic inflammation, alteration of microbial metabolites, and disruption of intestinal barrier integrity. Conversely, specific commensal bacteria have demonstrated protective effects against CRC initiation and progression, primarily by modulating immune responses, enhancing mucosal barrier function, and producing anti-tumorigenic metabolites. Promisingly, therapeutic interventions targeting gut microbiota, such as fecal microbiota transplantation and microbial-based therapeutics, hold potential for CRC prevention and treatment. However, achieving a comprehensive understanding of the complex interactions among host genetics, environmental factors, and the gut microbiota in CRC remains a critical research frontier. Advancements in high-throughput sequencing technologies, coupled with multi-omics approaches, are poised to unravel the nuanced mechanisms underlying gut microbiota-CRC interactions, ultimately paving the way for precision medicine strategies tailored to individual patients.
This Research Topic aims elucidate the pivotal role of gut microbiota in colorectal cancer (CRC), delving into its multifaceted implications for disease etiology, progression, and therapeutic interventions. By unraveling the intricate interplay between host-microbiota interactions and CRC pathogenesis, we seek to uncover novel biomarkers for risk assessment and prognosis, paving the way for precision medicine strategies. Additionally, our objective is to decipher the mechanistic underpinnings of dysbiosis-mediated carcinogenesis, informing the development of targeted microbiota-based therapeutics and dietary interventions. Ultimately, these endeavors aim to advance our understanding of CRC at the molecular level, fostering the translation of microbiome research into transformative clinical applications for improved patient outcomes.
We welcome submissions focused on, but not limited to, the following subtopics:
● Exploring the mechanisms underlying the involvement of gut microbiota in the occurrence, development, recurrence, metastasis, and treatment resistance of CRC.
● Unveiling the complex interplay between host-microbiota interactions and the pathogenesis of CRC, seeking novel biomarkers for risk assessment and prognosis.
● Clinical and basic research on the role of gut microbiota in early-onset CRC.
● Studying the co-cultivation of organoids and microbiota to elucidate mechanisms of colorectal development.
Keywords:
Gut microbiota, Colorectal cancer, Patient-derived organoids, Co-cultivation of organoids and microbiota, Early onset colorectal cancer
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.